 |
Male patients: 49%
Female patients: 41%
Gender unknown: 10% |
| |
|
 |
14 patients aged 1 - 29yrs
40 patients aged 30 - 59yrs
15 patients aged 60 - 89yrs |
| |
|
 |
44% of patients who took part in the survey were Caucasian. 25% were African; 12% were Asian; 10% were Afro-Carribean and 9% were of undisclosed origin. |
| |
|
 |
The reported number of attacks in one year experienced by the group before taking Yamoa was 78. Attacks dropped to 22 per year after Yamoa. |
| |
|
 |
On average patients took some form of asthma medication 3.6 times a day before taking Yamoa Powder.
The average number of times medication has been required on a daily basis since Yamoa has been taken is 1.7 times a day. |
| |
|
 |
There were 3 hospital admissions amongst the group who responded to the survey before Yamoa was taken. Afterwards, there were none before the survey was completed. |
| |
|
 |
The average peak flow rate reading taken before Yamoa was 350. The average taken since using Yamoa Powder was 420. This means an average improvement of 70. |
| |
|
 |
The shortest time since Yamoa Powder was taken at the time of the survey was 2 months. The longest time was 10 years (probably one individual). The average therefore was 16 months, but this will have been exaggerated by the person who took Yamoa 10 years ago. |
| |
|
 |
The longest time Yamoa was taken by a patient was 24 months. The shortest length of time Yamoa Powder was taken for was 0.5 months (two weeks), and the average time (increased by the unusual 24 month user) was 2.4 months. |
| |
|
 |
Before Yamoa was taken, the average number of irritants causing an asthma attack was 3. After Yamoa was taken this average was reduced to 1. |
| |
|
 |
12% of patients found no benefits from taking Yamoa.
19% experienced a mild improvemnt in their condition.
29% reported a CURE.
40% reported a marked improvement in their condition.
69%, that is 69 people in every 100, experienced AT LEAST a marked improvement in their asthma, as a result of taking Yamoa Powder. |
| |
|
 |
27 patients were Caucasian, 17 were african.
Of the Caucasian group, 19% of people reported a cure; 37% reported a marked improvement; 30% improved mildly, and 19% received no benefits.
Of the African group, 53% reported a cure; 41% reported a marked improvement; 6% reported mild improvement and 0% received no benefits at all from taking Yamoa for asthma. |
| |
|
 |
Age group 1-29:
0% received no benefits at all; 20% benefited mildly; 60% improved markedly and 20% reported a cure after taking Yamoa Powder.
Age group 30 - 59:
10% did not benefit from taking Yamoa Powder. 15% received a mild improvement; 39% achieved a marked improvement and 37% reported a cure after taking Yamoa Powder.
Age group 60 - 89:
38% did not benefit from taking Yamoa Powder. 31% received a mild improvement; 15% achieved a marked improvement and 15% reported a cure after taking Yamoa Powder.
Indications show that greater benefits may be achieved the younger the patient. This may be because the condition has not been with younger patients as long as for those in the older group; they may not have the history of stress and illness that older people have, in which case younger immune systems may be stronger than old. The younger group most likely does not have other contributing factors such as life-long smoking history etc. |
| |
|
